| Date | Title | Description |
| 07.07.2026 | RoosterBio and Qkine Partner to Deliver a Single-Source Platform to U.S. Customers | RoosterBio and Qkine Partner recently announced a partnership to deliver a single-source platform of cells, media, and growth factors to U.S. customers.
By bringing together high-quality cells, bioprocess media, and recombinant growth facto... |
| 24.02.2026 | bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution Hub | Following a strong $50M funding round, portfolio company bit.bio is leveraging scale and operational efficiencies to significantly lower the price per vial across its ioCells™ portfolio, expanding access to high-quality human cells globally... |
| 11.12.2025 | Xcell Biosciences and Culture Biosciences Announce AI/ML Partnership for Cell Therapy | Portfolio company Xcell Biosciences and Culture Biosciences are teaming up to bring AI, and machine learning-driven analytics to the AVATAR™ Foundry platform, empowering deeper insights and real-time optimization in cell therapy development... |
| 08.10.2025 | Alpenglow Biosciences and Virdx Announce Strategic Deal to Advance AI-Enabled Prostate Cancer Diagnostics | Portfolio company Alpenglow Biosciences announces a new multi-year collaboration with Virdx, an AI-driven biophysics company specializing in MRI-based cancer detection.
Together, they’re working to bridge radiology and pathology for prostat... |
| 07.10.2025 | RoosterBio & Secretome Therapeutics Announce Successful Completion of Large Scale Production for Clinical Stage Cell Therapy Candidate | Portfolio company RoosterBio, in partnership with Secretome Therapeutics, announced the successful completion of large-scale bioreactor production for Secretome’s clinical-stage cell therapy candidate, STM-01. The milestone marks a key step... |
| 01.10.2025 | ZEISS and Alpenglow Biosciences Unveil Inverted Light-Sheet Microscopy Platform for Clinical Applications | Portfolio company AlpenGlow Biosciences and the Ziess Group have partnered to revolutionizing digital pathology.
The partnership combining Alpenglow's 3D, AI-powered digital imaging platform with Ziess's expertise in light-sheet microscopy ... |
| 24.06.2025 | Xcell Biosciences Announces Joint Research Collaboration with Thermo Fisher Scientific to Advance the Next Gen Cell Therapies | Xcell Biosciences, one of Dynamk Capital’s standout portfolio companies and Thermo Fisher are working together to supercharge regulatory T cell (Treg) and tumor-infiltrating lymphocyte (TIL) therapies—next-gen treatments designed to tackle ... |
| 07.05.2025 | ZEISS and Alpenglow Biosciences partner for co-development of 3D pathology solution | Portfolio company, Alpenglow Biosciences have partnered with ZEISS to co-develop a 3D pathology platform that combines advanced light-sheet imaging with AI-powered analysis. This marks a major milestone for Alpenglow, as their technology mo... |
| 07.05.2025 | Curi Bio and Cook MyoSite Announce Strategic Partnership | Through this collaboration, portfolio company Curi Bio will integrate its versatile Mantarry 3D tissue engineering platform—compatible with diverse biological models and assays delivering clinically relevant functional outputs—with primary ... |
| 15.04.2025 | Rooster Bio enters into strategic licensing agreement with Nikon Cell Innovation | Big news from Dynamk Capital portfolio company Rooster Bio! Their strategic licensing agreement with Nikon Cell Innovation marks a major step forward in expanding access to GMP-grade MSCs and extracellular vesicles in Japan. This collaborat... |
| 08.04.2025 | Curi Bio Celebrates Grand Opening of New Global Headquarters in Seattle | We are thrilled to share that our portfolio company, Curi Bio has officially opened its new global headquarters in Seattle. This state-of-the-art facility enhances their capabilities to advance human-relevant drug discovery and development.... |
| 03.04.2025 | Xcellbio Announces Bluebird Bio Commercial Agreement to Tackle Sickle Cell Disease | Congratulations to our portfolio company xcellbio on this exciting progress in advancing cell and gene therapies for sickle cell disease.
This work is an important step toward making precision medicine more accessible and effective for pati... |
| 25.03.2025 | Alpenglow Biosciences Launches New Software Platform | Alpenglow Biosciences, a portfolio company of Dynamk Capital, recently unveiled LUMI, an intuitive user interface designed to streamline light-sheet microscopy, making high-throughput 3D imaging more accessible than ever. By redefining spat... |
| 20.03.2025 | Xcell Biosciences, Royal Perth Hospital Collaboration Announcement | Congratulations to portfolio company, Xcell Biosciences, for their collaboration with The Royal Perth Hospital to develop an automated, clinical-scale manufacturing workflow for therapies based on tumor-infiltrating lymphocytes (TILs) using... |
| 12.03.2025 | CellFE Launches First-in-Class T-REST™ Kit to Advance CAR-T Therapy Manufacturing | Portfolio company CellFE has unveiled the T-REST™ Kit, a groundbreaking solution designed to enhance CAR-T therapy manufacturing by improving T-cell fitness and function during cell engineering. This first-in-class kit integrates seamlessly... |
| 12.03.2025 | bit.bio Launches ioTracker™ Cells to Revolutionize Live-Cell Imaging and Drug Discovery | bit.bio, a Dynamk Capital portfolio company, has introduced ioTracker™ Cells, a new range of human iPSC-derived cells designed for precise live-cell imaging and drug discovery applications. These cells offer consistent, high-quality fluores... |
| 30.10.2024 | Virica Biotech is Building an Ecosystem to Ramp Up AAV Production | Portfolio company Virica Biotech made two recent collaboration announcements highlighting the industry embracing their cell enhancing platform for improving adeno-associated vectors (AAVs) production. Virica and eXmoor Pharma announced a ne... |
| 16.10.2024 | Lucid Scientific Highlighted by Memorial Sloan Kettering Cancer Center in The Scientist | In this latest issue of The Scientist, portfolio company Lucid Scientific's Recipher Platform is highlighted by researchers at Memorial Sloan Kettering Cancer Center as a novel way to measure live oxygen consumption rate (OCR) in cell cultu... |
| 19.08.2024 | Alpenglow Biosciences to receive up to $21M through ARPA-H as part of the Cancer Moonshot initiative | Portfolio company Alpenglow Bioscience, a company reshaping pathology with their 3D spatial biology platform, announced they were awarded up to up to $21M in contracts from Advanced Research Projects Agency for Health (ARPA-H) and the Natio... |
| 11.04.2024 | Virica Biotech Selected as a Lead Project as Part of NIIMBL's $10M Biomanufacturing Projects | Portfolio company, Virica Biotech has been included in a NIIMBL (The National Institute for Innovation in Manufacturing Biopharmaceuticals) $10M program as a lead project in a total of 8 biomanufacturing Projects. Virica's VSE platform help... |
| 05.03.2024 | Bit.bio makes two big announcements in Alzheimer’s and Parkinson’s research and collaboration | Portfolio company bit.bio made two big announcements. In addition to launching a panel of 16 opti-ox™ precision reprogrammed neurodegenerative disease models for research and drug discovery in Alzheimer’s and Parkinson’s, they announced the... |
| 26.02.2024 | Curibio Leverages Their 3D Neuromuscular Junction Model for Botox Potency Assay in Collaboration with Genetox and DreamCIS | Latest collaboration news on portfolio company Curi Bio. Curi Bio’s preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platf... |
| 07.02.2024 | Portfolio company RoosterBio Announce Collaboration with Waisman Biomanufacturing For GMP Manufacturing of Cell & Exosome Therapies | Portfolio company RoosterBio today announced a collaboration with Waisman Biomanufacturing to deliver an end-to-end solution for the development and manufacturing of cell and exosome-based therapeutics, including the critical raw materials,... |
| 13.11.2023 | bit.bio announces cell therapy pipeline and expanded Scientific Advisory Board | Portfolio company bit.bio, the company coding human cells for novel cures, announced its cell therapy pipeline, and declared its lead cell therapy candidate as it prepares to enter clinical development in 2025. The company also announced th... |
| 08.11.2023 | Virica Biotech Receives Grant through Ontario Genomics’ BioCreate accelerator | Portfolio company Virica Biotech has been selected for the Ontario Genomics’s BioCreate accelerator program. Virica plays a critical role in the Canadian biotech ecosystem, announcing in May it is part of the Canadian Pandemic Preparedness ... |
| 25.10.2023 | Cytiva & RoosterBio Collaborate to Address Exosome Manufacturing Challenges | Portfolio company Rooster Bio is partnering with Cytiva to solve the challenges of cost and quality by developing improved purification processes. Exosomes show great promise in gene therapies as a delivery vehicle to carry therapeutic mole... |
| 12.10.2023 | Daniella Kranjac Mesa Panel Featured in Gen Eng News | Featured in Genetic Engineering & Biotechnology News news the article summarized an exciting panel Founding Partner, Daniella Kranjac, participated in at the annula Cell and Gene on the Mesa presented by the Alliance for Regenerative Me... |
| 11.10.2023 | Portfolio Company Vectron Biosolutions and Cytovance Biologics Partner to Improve Development of Biologics | Vectron Biosolutions just announced a strategic, international partnership with Cytovance Biologics, a renowned leader in contract development and manufacturing services for biopharmaceuticals. This partnership will give the industry new, m... |
| 27.09.2023 | Portfolio company CellFE Biotech has closed their Series A funding round, securing $22 million in financing | The round was led by M Ventures , with participation from GreatPoint Ventures and Riverine Ventures, as well as existing investors at Cota Capital, Dynamk Capital, Elm Street Ventures, Embark Ventures, EGB Capital, and Khosla Ventures. The ... |
| 26.09.2023 | Lucid Scientific Secures $7 Million Series A Financing | Portfolio company, Lucid Scientific, announced the closing of a $7M Series A financing led by IAG Capital Partners. Additional participants include Lucid’s original investor base, the Georgia Research Alliance’s Venture Fund, and Dynamk Cap... |
| 20.09.2023 | Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research | Portfolio company Curi Bio, innovating human stem cell-based platforms for drug discovery, announced the commercial launch of its Nautilus™ and Stingray™ platforms for advancing preclinical drug discovery. As an integrated part of Curi Bio’... |
| 03.08.2023 | bit.bio and BlueRock Therapeutics announce collaboration to advance T cell (Treg) based therapies | Tregs play a crucial role in maintaining balance in the body’s immune system and iPSC-derived Treg based therapies have the potential to treat a broad range of autoimmune and inflammatory disorders.
bit.bio will use its machine learning po... |
| 02.08.2023 | Alpenglow awarded $1.6M grant to develop AI-enabled smart microscopy and 3D cancer database | Portfolio company Alpenglow Biosciences has been awarded a $1.6M grant by the Andy Hill, Washington’s Cancer Research Endowment (CARE) fund to develop an AI-enabled smart microscopy and a 3D cancer database. This development project will be... |
| 17.07.2023 | Albenglow Biosciences CEO, Nick Reder Featured in Recent Pharma's Almanac Interview | In this recent Pharma’s Almanac interview, Alpenglow CEO Nicholas Reder, M.D. explains the critical role of pathology in understanding the safety and efficacy of drugs and how Alpenglow is using a novel combination of 3D imaging, cloud comp... |
| 29.06.2023 | Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP Manufacturing | Portfolio company Vernal Biosciences, an innovative mRNA and LNP Contract Development and Manufacturing Organization (“CDMO”) announced the completion of a $20MM funding round, led by Ampersand Capital Partners and Charles River Labs with p... |
| 24.04.2023 | Virica Biotch To Expand Domestic Vaccine Manufacturing Capacity with Government Support | Portfolio company Virica Biotech recently announced a $790k grant from the Ontario Together Fund (“OTF”). The funding will support an expansion project which aims to grow Virica’s bioprocessing capacity to keep pace with client demand for s... |
| 12.04.2023 | Alpenglow Biosciences and Mayo Clinic enter collaboration agreement to advance pathology and drug development through 3D spatial biology | Alpenglow Biosciences collaboration with Mayo Clinic to integrate Alpenglow’s 3D spatial biology platform to accelerate drug development and advance clinical diagnostics. Alpenglow has created an end-to-end 3D spatial biology solution inclu... |
| 20.03.2023 | Portfolio Company Vectron Biosolutions Recently Published in Frontiers in Chemical Engineering | Vectron's CSO, Jostein Malmo, co-authored a recent article published in Frontiers in Chemical Engineering this week. The article gives valuable and detailed insights into the metabolic burden that recombinant protein production can cause to... |
| 15.03.2023 | Curi Bio Launches MantaReady™ 3D Skeletal Muscle Tissue Media | Portfolio company Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, expands its portfolio with the commercial launch of their MantaReady™ Skeletal Muscle Media optimized for human 3D engineered muscle tiss... |
| 15.03.2023 | RoosterBio & Repligen Collaborate to Advance Scalable Exosome Bioprocessing | Portfolio company Rooster Bio recently announced it has selected Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, as a collaboration partner to advance scalable exosome bioprocessing. Rooster Bio... |
| 16.02.2023 | Curi Bio Names Nicholas Geisse, Ph.D., as New Chief Executive Officer | Portfolio Company Curi Bio recently announce the new appointment of Nicholas (Nick) Geisse, Ph.D. as CEO to lead the organization. Dr. Geisse has been serving as the Chief Science Officer at Curi Bio since 2017. During that time, he was res... |
| 10.02.2023 | Portfolio Company BitBio Recently Announced a Partnership with Automata | Portfolio company BitBio recently announced a partnership with Automata, a leading life science lab robotics and automation company to automate a key aspect of the manufacturing process of their iPSC (induced pluripotent stem cell) products... |
| 10.02.2023 | Portfolio Company Envisagenics Featured in Recent Wuxi AppTec Interview | Maria Luisa Pineda, PhD, CEO and co-founder of Envisagenics was recently featured in WuXi AppTec’s interview series on the topic; Delivering on the Promise of New Modalities. Portfolio company Envisagenics focuses on diseases driven by spli... |
| 10.01.2023 | Sartorius Collaborates with RoosterBio to Advance Downstream Purification Processes for the Manufacture of Exosomes | In the latest news, Sartorius AG (Sartorius Stedim Biotech) will continue its strategic collaboration with portfolio company RoosterBio to advance downstream purification processes for the manufacture of exosomes. Through this collaboration... |
| 29.11.2022 | Portfolio Company Envisagenics enters into Multi-Year Collaboration with BMS | Today portfolio company, Envisagenics, announce a multi-year research collaboration agreement with Bristol-Myers Squibb. Together, they will leverage Envisagenics’ SpliceCore, a cloud-based AI Platform that identifies alternative splicing t... |
| 14.11.2022 | Daniella Kranjac Recognized in Fierce Pharma's "Fiercest Women in Life Sciences" 2022 | This prestigious list recognizes the women inspiring, leading, and building diversity in the Life Sciences industry across biotech, pharma, and medtech. Of 400 nominees, 20 were selected for the 2022 list. The full article highlights all 20... |
| 26.10.2022 | Portfolio Co. Vectron Biosolutions Partners with Plant-Based Foods Manufacturer | Branching outside of traditional biologics, Vectron Biosolutions will support Motif FoodWorks with their deep expertise in strain development and their proprietary gene expression technologies to create food-technologies that improve the ta... |
| 24.10.2022 | Portfolio Co. RoosterBio and FUJIFILM Announce Collaboration | FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies.
Press Release |
| 04.10.2022 | Dynamk Capital makes Inc. Magazine 2022 Founder-Friendly Investors list | Today Inc. Magazine announced their 2022 Founder-Friendly Investors list which included Dynamk Capital. The list boasts the best PE and VC firms with a track record of success backing entrepreneurs. We strive to help founder-led companies a... |
| 13.09.2022 | Daniella Kranjac nominated for "Lifetime Luminary" award at Biotech Week Boston | Dynamk Capital is excited to announce that Founding Partner, Daniella Kranjac has been nominated for a Biotech Week Boston (BWB) award in the “Lifetime Luminary” category. Daniella has played a critical role in the life science ecosystem bu... |
| 23.08.2022 | Portfolio Co. CEO Featured n Pharma's Almanac Article | Vectron Biosolutions CEO, Trond Erik Vee Aune, Ph.D. was recently featured in an article discussing the advantages of their custom expression technology for the optimization of bacterial protein production |
| 23.08.2022 | Portfolio Co. RoosterBio and AGC Biologics Announce Collaboration | RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies. The partnership creates an end-to-end solution for the development and production of hMSC and exosome therapeutics leveraging Roo... |
| 28.07.2022 | Dynamk Capital Nominated for the 2022 Prix Galien Awards | We are honored to be nominated for the 2022 Prix Galien “Best Digital Health Solution”, “Incubators, Accelerators and Equity” – Foundational Support for Health Innovation. The Prix Galien Awards have become the most coveted prize for those ... |
| 07.06.2022 | Dynamk Capital promotes Jessica Davis to Principal | Jessica Davis, Principal
Dynamk Capital today announced the promotion of Jessica Davis to Principal.
Since joining Dynamk Capital in 2020, Jessica has made many valuable contributions to the firm, evaluating several key investments and te... |
| 02.06.2022 | Dynamk Capital Co-Leads $21M Vernal Biosciences round along with Ampersand Capital Partners
Vernal Biosciences Raises $21 Million to Accelerate mRNA Manufacturing Growth |
COLCHESTER, Vt., June 2, 2022 /PRNewswire/ -- Vernal Biosciences, a technology-leading mRNA manufacturer and formulator of LNP-mRNA, announced today the completion of a $21 million financing to fully integrate its mRNA manufacturing solut... |
| 27.04.2022 | Bionter AG secures $3 Million in Series Seed Financing Led by Dynamk Capital | April 27, 2022, Riehen, Switzerland - Bionter AG, experts in sub-visible particle testing, announced the completion of a $3 million Series Seed financing from Dynamk Capital. Bionter revolutionizes analytical testing of subvisible particles... |
| 21.04.2022 | Portfolio Company Xcellbio expands Labcorp Collaboration for Cell & Gene Therapies | Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of cell and gene therapy technologies has expanded its collaboration with Labcorp to advance critical work that helps clients effectively bring innovative cell and gene therapies to ... |
| 01.04.2022 | Curi Bio Announces Technology Acquisition & Product Launch | Portfolio company Curi Bio announced the acquisition of CarTox™ Technology from StemBioSys & Launch of Nautilus™ Optical Mapping System.
Curi helps pharmaceutical partners develop safer, more effective therapeutics by providing drug de... |
| 03.02.2022 | Portfolio Company Lightspeed Microscopy, Inc. Rebrands to Reflect Expanded Offering and Vision | On February 1, 2022 Lightspeed Microscopy, Inc., announced the company will begin operating under the name Alpenglow Biosciences (Alpenglow). The company’s ownership and staff remain unchanged.
CEO, Nicholas Reder, MD, MPH stated “Our rebr... |
| 19.01.2022 | Dynamk Capital Joins World-Class Syndicate of LS Investors Participating in Xcellbio’s $27.5 Series B Round | Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of innovative technologies and platforms designed to further the research, development, and manufacturing of cell and gene therapies, announced $27.5 million in Series B financing le... |
| 04.01.2022 | Kayo announces Daniella Kranjac, Dynamk Capital as a Top 22 in ‘22: Women in Life Sciences | Kayo Life Sciences announcement: It was another momentous year for science in 2021 and 2022 shows no signs of slowing down. Opportunities and challenges alike fuel female founders and executives in the life science ecosystem to spark furthe... |
| 09.11.2021 | Dynamk Capital Hosts Inaugural Annual General Meeting | In October Dynamk hosted its first Annual General Meeting (AGM) for GPs, LPs, advisors, and partners. The agenda included:
The State of Dynamk; team, performance, vision
The State of the Life Science Industrials (LSI) market; financials, ... |
| 04.10.2021 | Virica Biotech Raises Series A Financing and Expands Operations to Support Manufacturing of Viral Medicines | OTTAWA, Ontario--(BUSINESS WIRE)--Virica Biotech Inc., a leading life science developer of solutions for scaling of viral medicines, announced today the first closing of its Series A financing. The round, led by Dynamk Capital, is expected ... |
| 29.09.2021 | Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform | Dynamk Portfolio Company, Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug discovery platform and... |
| 20.09.2021 | Dynamk announces Gregory Russotti, Ph.D. as Scientific Advisor | Dr. Gregory Russotti has been announced as the newest member of Dynamk Capital’s Scientific Advisory team of industry experts. Dr. Russotti brings a wealth of knowledge in cell therapy process development and manufacturing. He has a deep un... |
| 17.06.2021 | Vectron Biosolutions to Boost Protein Production Offering with Acquisition of Secretion Platform from T3S Technologies and $2.7M Series A Financing Round | Trondheim, Norway – June 17, 2021, Vectron Biosolutions, upstream experts providing expression tools and services in biomanufacturing, announced today it has raised $2.7 million in a Series A financing round led by Dynamk Capital as well as... |
| 15.06.2021 | Lightspeed Microscopy, Inc. raises $4M in Series A Financing Round with Plans to Revolutionize Pathology | Seattle, WA – June 15, 2021, Lightspeed Microscopy, Inc., an end-to-end 3D pathology platform, announced today it has raised $4 million in a Series A financing round. The round was led by Dynamk Capital and is expected to close with partici... |
| 26.05.2021 | Dynamk Capital names Jessica Davis, Senior Associate | Jessica Davis, Senior Associate
Dynamk Capital announced today the addition of Jessica Davis, Senior Associate, to our growing Dynamk team.
Jessica has worked with us as an Associate during the summer of 2020 and while she pursued her MBA... |
| 27.04.2021 | Dynamk Capital Announces Final Closing of its Life Science Industrials Fund | New York, NY – April 27, 2021 – Dynamk Capital LLC, a venture fund providing early stage and growth capital to innovative Life Science Industrials companies, today announced the final closing of its first fund, Dynamk Life Sciences Fund L.P... |
| 18.03.2021 | Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms | Seattle, WA – March18, 2021 – Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced today it has raised $6 million in a Series A financing round. The round, led by Dynamk Capital, is expected to... |
| 05.01.2021 | Dynamk Capital Promotes Sebastien Latapie to Principal | Sebastien Latapie
Dynamk Capital today announced the promotion of Sebastien Latapie to Principal. Since joining Dynamk as a Senior Associate in 2019, Sebastien has helped source, screen and evaluate several key investments and technologies... |
| 11.10.2020 | Dynamk Capital talks the Future of Healthcare with Pharma’s Almanac | - |
| 01.10.2020 | Dynamk featured in Pharma’s Almanac article on disruptive Organ-on-a-Chip | Read more here. |
| 01.10.2020 | Lucid Scientific Secures $3 Million in Series Seed Financing Led by Dynamk Capital | Maker of real-time cell analysis systems plans capacity expansion in production, customer success, and direct sales to meet growing demand.
ATLANTA, Georgia (September 30, 2020) — Lucid Scientific, the biotechnology tools company that deve... |
| 13.07.2020 | Dynamk Launches Industry Insights Newsletter: Quarterly Trends, Transactions & Headlines | Proud to launch the first installment of our Life Science Industrials Insights newsletter covering Quarterly trends, transactions and noteworthy headlines!
Read the first newsletter here. |
| 07.04.2020 | Dr. Gustavo Mahler Now a General Partner at Dynamk Capital | Dr. Gustavo Mahler
NEW YORK, New York, April 7, 2020 /PRNewswire/ — Dynamk Capital, a growth equity and venture capital and private equity firm focused on life science industrials, announced today that Dr. Gustavo Mahler has become a Gener... |
| 16.01.2020 | CellFE Raises $3.6 Million in Series Seed Round Co-Led by Dynamk Capital and Cota Capital | San Carlos, CA – January 16, 2020 – CellFE, Inc., an innovative startup developing a microfluidics based device to deliver gene-editing molecules, today announced it has raised $3.6 million in an initial Series Seed. The oversubscribed roun... |
| 10.01.2020 | Dynamk Capital participates in Life Science Investor Panel during JPMorgan Healthcare Week | San Francisco, CA – January 14, 2020 – RESI Redefining Early Stage Investments Conference 2020 Life Science Tools Panel Discussion
Join panelists from Arch Ventures, Agilent, Dynamk Capital, Nanodimension and others.
While new breakthroug... |
| 05.11.2019 | Dynamk Capital sponsors Life Sciences Washington VIP Forum | Seattle, WA – November 20-21, 2019 – Join Dr. Gustavo Mahler, Daniella Kranjac and Sebastien Latapie as they host entrepreneurs and university spinouts interested in Life Science Industrials together with Life Science Washington and the LSW... |
| 10.10.2019 | FloDesign Sonics Acquired by MilliporeSigma | Dynamk Capital is pleased to announce that FloDesign has closed a merger transaction with MilliporeSigma announced on October 10, 2019.
Burlington, Massachusetts, October 10, 2019 — MilliporeSigma today announced it has acquired FloDesign ... |
| 06.08.2019 | RoosterBio Raises $15 Million in Series B Round Led by Dynamk Capital | FREDERICK, MD and NEW YORK, NY – August 6, 2019 – RoosterBio Inc, disrupting the market by radically simplifying human mesenchymal stem/stromal cell (hMSC) biomanufacturing, today announced it has raised in excess of $15 million in an initi... |
| 29.05.2019 | Dr. Gustavo Mahler joins Dynamk Capital as Venture Partner | Dr Gustavo Mahler
Dr. Gustavo Mahler joins Dynamk Capital as a Venture Partner after leaving his 10 year tenure with AGC Biologics (formerly CMC Biologics). Under his leadership as CEO of AGC Biologics, the company grew to become a leader ... |
| 27.05.2019 | Dynamk Capital names Sebastien Latapie, Senior Venture Associate | Sebastien Latapie
Dynamk Capital announced today the addition of Sebastien Latapie, Senior Venture Associate, to our growing team of investors, operators and advisors.
Sebastien has been working at the intersection of healthcare and techn... |
| 07.01.2019 | Dynamk Capital Announces New Partner, Reinhard Vogt | Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science companies, announces today the addition of Reinhard Vogt as a Partner, effective immediately. Reinhard joins the fund currently led by Daniel... |
| 11.11.2018 | Dynamk participates in the Global Family Office Investment Summit, Dubai | Daniella Kranjac, Founding Partner of Dynamk Capital, talks Life Science and Biotech trends at the Global Family Office Investment Summit, November 10-12, 2018, Dubai, UAE.
|
| 19.06.2018 | Dynamk Announces Advisory Team | Kevin Bailey, PhD
Barry Buckland, PhD
Anthony Maddaluna
Gustavo Mahler, PhD
Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science tools and service providers, announces their all-star list of... |
| - |
CellFE Secures $4.8M Seed Round Funding Co-led by Dynamk Capital and Cota Capital | News provided by
Mar 31, 2020, 06:00 ET
Share this article
SAN CARLOS, Calif., March 31, 2020 /PRNewswire/ -- CellFE, Inc., an innovative startup developing a microfluidics based device to deliver gene-editing molecules, today announced ... |
